Why the study?
Does trimetazidine MR improve parameters of 24-hour ECG monitoring and heart rate variability in patients with stable coronary heart disease?
Does trimetazidine MR improve parameters of 24-hour ECG monitoring and heart rate variability in patients with stable coronary heart disease?
Trimetazidine MR provides an additional anti-ischemic effect by reducing ST segment depression and ischemic episode duration in patients with stable CHD.
Answers are grounded in this paper and cite their sources.
May support adjunctive trimetazidine MR for ischemia reduction in stable CHD; leaves open confirmation in randomized trials.
Aim. To assess the effects of the four-month trimetazidine MR therapy on the parameters of 24-hour electrocardiogram (ECG) monitoring and heart rate variability (HRV) in patients with stable coronary heart disease (CHD). Material and methods. This prospective, non-randomised study, with the inclusion of 66 consecutive patients who had stable CHD and stable stress test results, investigated the effects of trimetazidine MR therapy on the parameters of 24-hour ECG monitoring and HRV. Results. Trimetazidine MR did not markedly affect the 24-hour, daytime, or nighttime levels of heart rate. Trimetazidine MR therapy was not associated with any substantial changes in frequency and time-domain HRV parameters or in the incidence of cardiac arrhythmias. However, there was a significant reduction in the number of patients with ST segment depression (from 66,7% to 43,8%; p<0,001) and in the duration of ischemic episodes (from 10 (6,2;21) minutes to 7,42 (5;12,3) minutes (p=0,025)). Conclusion. Adding trimetazidine MR to the treatment of patients with stable CHD provides an additional beneficial antiischemic effect.
No takes yet. Share an insight, caveat, or question.
Novikova et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: